BIO-RAD DIGITAL PCR SYSTEM AND TEST FOR MONITORING CHRONIC MYELOID LEUKEMIA TREATMENT RESPONSE
Bio-Rad Laboratories, Inc. has announced that its QXDx AutoDG ddPCR System, which uses
Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first
digital PCR products to receive FDA clearance. Used together, Bio-Rad’s system and kit can
precisely and reproducibly monitor molecular response to treatment in patients with chronic
myeloid leukemia. The QXDx AutoDG ddPCR System is designed to be flexible, allowing users
to run either FDA-cleared in vitro diagnostic tests or lab developed tests on the platform.
QIAGEN ONCOLOGY AND
IMMUNO-ONCOLOGY PANELS
QIAGEN
QIAGEN has launched three innovative sample to insight workflows
for NGS research in oncology using QIAGEN’s GeneReader
NGS System and other NGS platforms. Two new GeneRead
QIAact panels for use on QIAGEN’s GeneReader NGS System
deliver more powerful genomic insights, one covering a broad
range of cancer-causing variants and the other focusing on genes
tied to breast and ovarian cancers. Additionally, a new QIAseq
panel was launched for use on any NGS system to measure tumor
mutational burden, an emerging biomarker for use in assessing
how a patient may respond to checkpoint inhibitors, which are a
form of cancer immunotherapy.
ROCHE NAVIFY® CLINICAL DECISION
SUPPORT APPS
Roche has launched the first two NAVIFY® clinical decision support apps to help oncology care teams access relevant clinical trial information and publications more effectively. Finding the most relevant up-to-date clinical trials and relevant literature is a cumbersome and labor-intensive process. The two launched apps available on the NAVIFY Tumor Board facilitate this process. The NAVIFY Clinical Trial Match app identifies clinical trial options based on patient-specific attributes such as age, gender, biomarkers, and various tumor information from 11 international registries. The NAVIFY Publication Search app mines publication sources globally for the most recent clinically and therapeutically relevant literature.
THERMO FISHER SCIENTIFIC ONCOMINE DX TARGET TEST
Thermo Fisher Scientific announced that it has CE-IVD marked its NGS-based
solution that screens biomarkers across solid tumors. Oncomine Dx Target Test
is CE marked as an in vitro diagnostic for detection of 46 cancer-driver gene
variants. All biomarkers on the panel are associated with approved and investigative
targeted therapies in solid tumors, including EGFR, BRAF, KRAS, and ERBB2
mutations, as well as ALK, ROS1, RET, NTRK, and MET fusions. It is also validated
as a companion diagnostic for approved therapies in non-small cell lung cancer,
including ALK, ROS1, and BRAF kinase inhibitors, as well as EGFR exon 19 deletions
and L858R tyrosine kinase inhibitors.
